C21 Investments Bucks Nevada Cannabis Decline with Record Growth and a High-Stakes Tax Play

VANCOUVER, BC – June 12, 2026 – In an industry defined by volatility and regulatory hurdles, C21 Investments Inc. has delivered a masterclass in operational resilience. The vertically integrated cannabis company just reported its fiscal year-end results, painting a picture of robust health that stands in stark contrast to the market it primarily serves. While overall cannabis sales in Nevada plummeted by 10%, C21 posted an 8.3% increase in annual revenue to $32.6 million, driven by a record 725,000 customer transactions.

This counter-cyclical performance is not merely a statistical anomaly; it is the result of a deliberate strategy combining operational excellence, deep-seated customer loyalty, and an audacious financial gambit. The company is not just navigating the turbulent waters of the U.S. cannabis market—it is actively challenging the very currents that hold the industry back, most notably through a direct confrontation with the IRS over the punitive Section 280E tax code. This blend of grassroots execution and high-level strategy offers a compelling case study in how to build a durable enterprise in one of the world's most challenging sectors.

Defying Gravity in the Silver State

The story of C21's fiscal 2026 success is one of swimming against a powerful tide. The broader Nevada cannabis market has been grappling with a post-boom slump, characterized by price compression, waning tourism, and intense competition. Research shows statewide sales have been in steady decline, with some months seeing year-over-year drops as high as 16%. Yet, C21 managed to increase its revenue, driven by a remarkable 9.1% growth in retail sales.

According to CEO and President Sonny Newman, the outperformance is no accident. "Our performance is rooted in the fundamentals that have long differentiated our business: high-quality products, a trusted retail experience, loyal customers, and consistent execution," he stated in the company's earnings release. This isn't just executive rhetoric; the numbers bear it out. The company's 16% year-over-year increase in customer transactions demonstrates a growing and loyal customer base that is choosing C21's brands, like Silver State Relief, even as overall consumer spending in the state tightens.

A prime example of this strategy's success is the company's South Reno location, which has seen an explosive 143% in organic sales growth since its first full month of operations. This suggests C21 is not just retaining customers but actively capturing market share from competitors who are struggling to adapt to the new market realities. By focusing on the tangible aspects of the customer experience and product quality, the company has built a defensive moat that insulates it from broader market pressures.

The High-Stakes Bet on Tax Code 280E

Perhaps the most telling aspect of C21's strategy is its aggressive—and potentially transformative—challenge to Section 280E of the U.S. Internal Revenue Code. This decades-old provision, designed to penalize traffickers of Schedule I or II controlled substances, forbids cannabis companies from deducting standard business expenses like rent, payroll, and marketing. The result is an astronomical effective tax rate that can cripple even profitable operators.

C21's financial statements starkly illustrate this burden: the company generated a healthy $1.4 million in Net Income Before Tax, a 249% increase year-over-year. However, a staggering $4.6 million income tax expense pushed the company to a net loss of $3.2 million. Rather than accept this as the cost of doing business, C21 has taken the bold step of refiling amended federal tax returns for multiple prior years, asserting that it does not owe taxes attributable to 280E based on its legal interpretations.

This is a high-stakes gambit. The IRS has historically maintained a rigid stance, and legal battles, such as the ongoing New Mexico Top Organics v. Commissioner case, show the agency is not backing down. However, the landscape is shifting. The recent move by the Drug Enforcement Administration (DEA) to reschedule cannabis to Schedule III is expected to nullify 280E for future tax years. C21's legal challenge appears aimed at clawing back past payments, a move that, if successful, could unlock significant capital and set a powerful precedent for the entire industry. "It’s an aggressive posture, but one that reflects a calculated risk," noted one legal expert familiar with cannabis tax law. "The potential reward is a complete revaluation of the company's profitability and cash flow."

Building a Fortress of Fundamentals

While the 280E challenge represents a potential windfall, C21's current stability is built on a foundation of strong financial discipline. The company's focus extends beyond top-line revenue to the core metrics that signal long-term health. Adjusted EBITDA, a key measure of operational profitability, rose 13% to $5.5 million for the year. More importantly, Free Cash Flow before working capital changes and taxes also grew 13% to $4.6 million.

This robust cash generation is the engine that powers the business, allowing C21 to invest in growth, manage its obligations, and return value to shareholders without relying on dilutive capital markets. During the year, the company reduced its current liabilities by $1.6 million and repurchased 479,000 of its own shares—a clear signal of management's confidence in the company's intrinsic value and its commitment to a disciplined capital allocation strategy.

The consistent growth in customer traffic and free cash flow demonstrates that C21's model is not only resilient but sustainable. While competitors may be forced into a cycle of price wars and margin erosion, C21's focus on operational efficiency and brand loyalty allows it to generate the cash needed to weather market downturns and strategically invest in future growth, such as its recent agreement to acquire a purpose-built dispensary in Southern Reno to expand its retail footprint.